- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.
A brain volume quantification tool that may provide early insights on neurodegenerative conditions based on magnetic resonance imaging (MRI) assessment, the artificial intelligence (AI)-enabled NeuroShield has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Currently being utilized in over 200 facilities across the world, NeuroShield offers automated brain volume assessment based upon 3D MRI scans, according to InMed.AI (InMed Prognostics), the developer of NeuroShield.
The company noted that the brain segmentation analysis provided with NeuroShield has demonstrated high accuracy rates across different clinical subgroups and magnetic strengths in a trial of 280 subjects. InMed.AI noted that NeuroShield may aid in the early detection of brain atrophy, possibly facilitating timely intervention for those at risk of dementia, Alzheimer’s disease and other neurodegenerative conditions.
“We believe that investing in our collective human future and that technology is a great lever to move towards precision health to extend quality of life,” added Latha Poonamallee, Ph.D., the founder and CEO of InMed Prognostics.
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.
